CN116535461A - 一种四肽化合物tp-3及制备方法和用途 - Google Patents
一种四肽化合物tp-3及制备方法和用途 Download PDFInfo
- Publication number
- CN116535461A CN116535461A CN202310678726.XA CN202310678726A CN116535461A CN 116535461 A CN116535461 A CN 116535461A CN 202310678726 A CN202310678726 A CN 202310678726A CN 116535461 A CN116535461 A CN 116535461A
- Authority
- CN
- China
- Prior art keywords
- reaction
- gly
- mmol
- leu
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 97
- 238000007259 addition reaction Methods 0.000 claims abstract description 15
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000002192 fatty aldehydes Chemical class 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 claims 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 claims 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 claims 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract description 32
- 239000002904 solvent Substances 0.000 abstract description 22
- 239000003054 catalyst Substances 0.000 abstract description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 14
- 239000001257 hydrogen Substances 0.000 abstract description 14
- 238000005575 aldol reaction Methods 0.000 abstract description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract description 2
- 150000002576 ketones Chemical class 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 81
- 239000000243 solution Substances 0.000 description 80
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
- 238000003756 stirring Methods 0.000 description 42
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 21
- 239000007788 liquid Substances 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000006555 catalytic reaction Methods 0.000 description 7
- 238000000967 suction filtration Methods 0.000 description 7
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- -1 3-substituted succinimide Chemical class 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- IYMZEPRSPLASMS-UHFFFAOYSA-N 3-phenylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C=CC=CC=2)=C1 IYMZEPRSPLASMS-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000005002 aryl methyl group Chemical group 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000021513 Cinchona Nutrition 0.000 description 2
- 241000157855 Cinchona Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000006757 chemical reactions by type Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UJOYFRCOTPUKAK-MRVPVSSYSA-N (R)-3-ammonio-3-phenylpropanoate Chemical compound OC(=O)C[C@@H](N)C1=CC=CC=C1 UJOYFRCOTPUKAK-MRVPVSSYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HIDBROSJWZYGSZ-UHFFFAOYSA-N 1-phenylpyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=CC=C1 HIDBROSJWZYGSZ-UHFFFAOYSA-N 0.000 description 1
- LMIZLNPFTRQPSF-UHFFFAOYSA-N 2-azaniumyl-2-(2-chlorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=CC=C1Cl LMIZLNPFTRQPSF-UHFFFAOYSA-N 0.000 description 1
- NJBCRXCAPCODGX-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CNCC(C)C NJBCRXCAPCODGX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- WUACDRFRFTWMHE-UHFFFAOYSA-N 3,4-diaminocyclobut-3-ene-1,2-dione Chemical compound NC1=C(N)C(=O)C1=O WUACDRFRFTWMHE-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000005712 Baylis-Hillman reaction Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明公开一种四肽化合物及其制备方法及用途。本发明的四肽化合物为如式1示TP,
Description
技术领域
本发明涉及一种四肽化合物及制备方法和用途。确切讲本发明是一种四肽化合物及制备方法与用途,特别是一种可应用于催化脂肪醛与马来酰亚胺的不对称共轭加成反应的化合物及制备方法与用途。
背景技术
光学活性化合物是自然界的普遍现象,在细胞和生物体的生命活动过程中发挥着无可替代的作用。许多药物都有光学活性,手征性是药物的一个重要要素。用手性催化剂催化不对称反应是合成手性化合物最为经济、绿色的方法。不对成催化包含了三个领域,即手性配体-金属复合物催化剂、有机小分子催化剂和生物酶催化反应。由于绿色和良好的经济性能,生物酶催化一直是不对称催化的热点研究领域,但是由于酶蛋白结构的复杂性、易失活、专一性等因素限制了其快速应用。多肽是按照酶催化机理设计并合成的一类新型有机催化剂,具有结构简单、易合成、底物范围广泛、适应反应类型多、反应条件温和、结构稳定等诸多优势,是天然酶的优良模拟物,是化学生物学研究的重点方向。
已有报道证明,人工合成的短肽可以较好地替代天然蛋白酶,并模拟酶催化一系列化学反应,被广泛地应用于催化如Aldol、Michael、Stetter、叠氮化、Strecker、Baylis-Hillman、烯丙基取代、氰氢化、环氧化、氢化和酰基化等诸多不对称反应中,合成多种光学活性化合物,有效地克服了蛋白酶催化反应底物专一性和反应类型单一的缺陷,拓展了反应的类型和底物,适合于多种反应条件,并基本保持了生物催化反应绿色、经济的优点[(1)刘爱香,傅尧,刘磊,郭庆祥,有机化学,2007,27, 1195-1219. (2) Davie, E. A. C.;Mennen, S. M.; Xu, Y.; Miller, S. J.Chem. Rev.2007,107, 5759-5812. (3)Wennemers, H.Chem. Commun.,2011,47, 12036–12041. (4) Lewandowski, B.;Wennemers, H.Curr. Opin. Chem. Biol.2014,22, 40–46. (5) Kelly, D. R.;Roberts, S. M.Biopolymers2006,84, 74–89. (6) Akagawa, K.; Kudo, K.Acc. Chem. Res.2017,50, 2429-2439. (7) Ball, Z. T.Acc. Chem. Res.2012,46, 560-570.]。因而,发现新型高效的短肽催化剂模拟蛋白酶催化有机化学反应,一直是手性化合物合成领域的热点。
在不对称催化条件下,亲核试剂与N-取代马来酰亚胺的不对称共轭加成反应合成的手性3-取代琥珀酰亚胺,经过还原可以方便地转变成一系列手性吡咯化合物。手性吡咯化合物是许多生物活性化合物的核心骨架,不对称合成手性吡咯化合物一直是有机化学与药物化学研究的一个核心课题。此外,手性3-取代的琥珀酰亚胺经过水解反应也可以方便地转换为手性琥珀酸,是很重要的生理活性化合物以及手性合成砌块。醛作为亲核试剂与马来酰亚胺的不对称共轭加成产物,额外具有一个很容易衍生为其它官能团的有效基团,使得该反应具有重要的应用价值。因而持续开发高效的手性催化剂催化脂肪醛与马来酰亚胺的不对称共轭加成反应,是许多研究机构追求的一个目标。总结文献报道,成功应用于这一反应的催化剂基本上都是手性有机催化剂,绝大部分都是手性环己二胺为原料衍生的伯胺类硫脲或方酰胺催化剂,取得了理想的产率和对映选择性 [(8)Xue, F.; Liu, L.;Zhang, S.; Duan, W.; Wang, W.Chem. Eur. J.2010,16, 7979-7982; (9) Ma, Z.-W.;Liu, Y.-X.; Zhang, W.-J.; Tao, Y.; Zhu, Y.; Tao, J.-C.; Tang, M.-S.Eur. J. Org. Chem.2011, 6747-6754. (10) Orlandi, S.; Pozzi, G.; Ghisetti, M.;Benaglia, M.New J. Chem.2013,37, 4140-4147. (11) Yu, F.; Jin, Z.; Huang, H.;Ye, T.; Liang, X.; Ye, J.Org. Biomol. Chem.2010,8, 4767-4774. (12) Bai, J.-F.; Peng, L.; Wang, L.-L.; Wang, L.-X.; Xu, X.-Y.Tetrahedron2010,66, 8928-8932. (13) Ma, Z.-W.; Liu, Y.-X.; Li, P.-L.; Ren, H.; Zhu, Y.; Tao, J.-C.;Tetrahedron: Asymmetry 2011,22, 1740-1748. (14) Ma, Z.-W.; Liu, X.-F.; Liu,J.-T.; Liu, Z.-J.; Tao, J.-C.Tetrahedron Letters2017,58, 4487-4490.]。金鸡纳碱硫脲和2-氯苯基甘氨酸作为一个高效的双催化剂体系,同样取得了理想的产率和对映选择性[(15) Muramulla, S.; Ma, J.-A.; Zhao, J. C.-G.Adv. Synth. Catal.2013,355,1260-1264]。金鸡纳碱衍生的手性伯胺在添加三苯基膦的条件下,其催化产率与对映选择性均非常理想[(16) Yang, W.; Jiang, K.-Z.; Lu, X.; Yang, H.-M.; Li, L.; Lu,Y.; Xu, L.-W.Chem. Asian J.2013,8, 1182-1190]。在添加碱金属条件下发现,β-苯丙氨酸、天冬氨酸-a-叔丁酯以及侧链叔丁基保护的苏氨酸、异亮氨酸催化这一反应都取得了很好的不对称催化效果[(17) Kokotos, C. G.Org. Lett.2013,15, 2406-2409. (18)Nugent, T. C.; Sadiq, A.; Bibi, A.; Heine, T.; Liu L.; Vankova, N.; Bassil,B. S.Chem. Eur. J.2012,18, 4088-4098]。也有一例二肽Ala-Ala催化该丙醛与马来酰亚胺反应的报道,其产物的ee值只有38% [(19) Zhao, G.-L.; Xu, Y.; Sundén, H.;Eriksson, L.; Sayah, M.; Córdova, A.Chem. Commun.2007, 734–735.]。因而开发应用于这一反应的高效多肽催化剂,是一个具有挑战性的工作。
发明内容
本发明提供一种可克服现有技术不足,可以高效率、不对称地催化脂肪醛与马来酰亚胺的共轭加成反应的化合物。
本发明所述的四肽化合物如式1所示TP,
其中:R1和R2分别是C1 ~ C6的任意直链烷基、支链烷基、环烷基、羟基取代烷基、巯基取代烷基、甲硫基取代烷基、氨基取代烷基、胍基取代烷基、芳基、芳甲基或杂原子芳基中的任一种。
优选地,本发明的四肽化合物,其R1和R2分别是C1 ~ C4的任意直链烷基、支链烷基、环己基、苯基、苯甲基中的任一种。
更为具体地,本发明所述的四肽化合物,其R1=i-Pr, R2=i-Bu,即:其氨基酸序列为H2N-D-Val-Pro-Gly-D-Leu-OH,命名为TP-1。
或者,本发明所述的四肽化合物,其R1=t-Bu, R2=i-Bu,即:其氨基酸序列为H2N-D-Tle-Pro-Gly-D-Leu-OH,命名为TP-2。
或者,本发明所述的四肽化合物,其R1= Ph, R2=i-Bu,即:其氨基酸序列为H2N-D-Phg-Pro-Gly-D-Leu-OH,命名为TP-3。
或者,本发明所述的四肽化合物,其R1=c-hex, R2=i-Bu,即:其氨基酸序列为H2N-D-Chg-Pro-Gly-D-Leu-OH,命名为TP-4。
或者,本发明所述的四肽化合物,其R1= Bn, R2=i-Bu,即:其氨基酸序列为H2N-D-Phe-Pro-Gly-D-Leu-OH,命名为TP-5。
或者,本发明所述的四肽化合物,其R1= Bn, R2= Bn,即:其氨基酸序列为H2N-D-Phe-Pro-Gly-D-Phe-OH,命名为TP-6。
本发明的四肽化合物制备方法,其反应历程如式2、式3、式4和式5所示,即:
将甘氨酸1、氨基酸2、缩合试剂C-1和添加剂A-1加入溶剂S-1搅拌反应,得到产物3,再将产物3和脱保护剂D-1加入溶剂S-2搅拌反应,得到产物4;
将产物4、脯氨酸5、缩合试剂C-2和添加剂A-2加入溶剂S-3中搅拌反应,得到产物6,再将产物6和脱保护剂D-2加入溶剂S-4中搅拌反应,得到产物7;
将产物7、氨基酸8、缩合试剂C-3和添加剂A-3加入溶剂S-5中搅拌反应,得到产物9,再将产物9和脱保护剂D-3加入溶剂S-6中搅拌反应,得到产物10;
将产物10和催化剂Pd/C加入溶剂S-7中,通入压力为1~30 Mpa氢气进行反应,得到终产物四肽TP,其中:
R3是芳基甲基;
R4、R5、R6是Boc(叔丁氧甲酰基)、Cbz(苄氧甲酰基)或Fmoc(芴甲氧甲酰基)中的任一种;
缩合试剂C-1、C-2和C-3是碳二亚胺、烷氧甲酰氯或R7OCOCl中的任一种,R7是C1 ~C4的任意直链烷基或支链烷基;
添加剂A-1、A-2和A-3是指R8R9R10N或NMM(N-甲基吗啉)或TMEDA(4-二甲氨基吡啶)或HOBt(1-羟基苯并三氮唑),R8、R9、R10是C1 ~ C4的任意直链烷基或支链烷基;
溶剂S-1、S-2、S-3、S-4、S-5、S-6是甲苯、苯、二氯甲烷、二氯乙烷、乙醚、四氢呋喃、乙二醇二甲醚、甲基叔丁基醚、环氧六烷、乙酸乙酯、乙酸甲酯、乙腈或丙腈中的任一种或任数种的组合,溶剂S-7是甲醇、乙醇、丙醇或丁醇中的任一种或任数种的组合;
脱保护剂D-1、D-2和D-3是甲基磺酸、三氟甲磺酸、苯磺酸、对甲苯磺酸、三氟乙酸、三氯乙酸、盐酸、硫酸、哌啶、吗啉、四氢吡咯、二氢吡咯、吡咯、二乙胺、二丙胺、二丁胺、二异丙胺或二异丁胺中的任一种。
优选地,本发明所述的化合物制备方法是其中:
R3是苄基;
R4、R5、R6是指Boc或Cbz;
缩合试剂C-1、C-2和C-3是DCC(N,N'-二环己基碳二亚胺)或DIC(N,N'-二异丙基碳二亚胺)或烷氧甲酰氯R7OCOCl,R7是Et或i-Pr或i-Bu;
添加剂A-1、A-2和A-3是TEA(三乙胺)、DIPEA(二异丙基乙胺)、NMM或HOBt中的任一种;
溶剂S-1、S-2、S-3、S-4、S-5和S-6是二氯甲烷或四氢呋喃,溶剂S-7是甲醇或乙醇;
脱保护剂D-1、D-2和D-3是甲基磺酸或三氟甲磺酸或三氟乙酸。
优选地,本发明所述的化合物制备方法是其中:
R3是苄基;
R4、R5 和R6是Boc;
缩合试剂C-1、C-2和C-3是DCC或DIC或烷氧甲酰氯R7OCOCl,R7是Et或i-Pr或i-Bu;
添加剂A-1、A-2和A-3是指TEA、DIPEA、NMM或HOBt中的任一种;
溶剂S-1、S-2、S-3、S-4、S-5、S-6是指二氯甲烷或四氢呋喃,溶剂S-7是指甲醇;
脱保护剂D-1、D-2和D-3是指三氟乙酸;
氢气压力是8Mpa。
本发明所述的化合物可用于酮与芳香醛的Aldol反应,或者用于如式6所示催化脂肪醛与马来酰亚胺的不对称共轭加成反应。即:将式6所示的脂肪醛11、
马来酰亚胺12和四肽TP加入含溶剂S-8的反应容器中搅拌,得到共轭加成反应的产物3-取代琥珀酰亚胺(R)-P,其中:
R11是氢或C1 ~ C6的任意直链烷基或支链烷基或苯基或苯甲基,R12是C1 ~ C6的任意直链烷基或支链烷基或苯基或苯甲基,或-R11-R12-是环己基或环戊基,R13是氢或苯基或取代苯基或直链烷基或环烷基或芳甲基;
四肽TP是如式1所示含两个末端D-型-α-伯氨基酸的四肽;
在上述反应中,溶剂S-8是指二氯甲烷、氯仿、二氯乙烷、乙酸乙酯、乙酸甲酯、甲苯、苯、二甲苯、乙醚、四氢呋喃、乙二醇二甲醚、甲基叔丁基醚、乙腈、丙腈、乙醇、甲醇、丙醇、丁醇中的任一种或多种。
优选地:
R11是氢或甲基或乙基,R12是甲基或乙基或异丙基或正丁基,或-R11-R12-是环己基或环戊基,R13是氢或甲基或环己基或苯甲基或苯基或取代苯基,取代苯基是指对甲基苯基或对氯苯基或对溴苯基或对氟苯基或对硝基苯基或对甲氧基苯基;
四肽TP是前述TP-1~TP-6中的任一种;
溶剂S-8是二氯甲烷、乙腈、乙醇、四氢呋喃、二甲基亚砜、甲苯中的任一种。
更优选地四肽TP是TP-3;溶剂S-8是乙腈。
本发明用于制备式1示化合物TP的中间化合物为:如式3示6或者如式3示7或者如式4示9或者如式4示10。
本发明的化合物在不对称催化的脂肪醛与马来酰亚胺共轭反应过程中可以高产率、高对映选择性地催化脂肪醛与马来酰亚胺的共轭加成反应。根据相关实验,本发明的四肽化合物可以高效率、不对称地催化脂肪醛与马来酰亚胺的共轭加成反应,反应的产率达到98%,对映选择性最高达到了99%,应用前景良好。
具体实施方式
本发明以下结合实施例进行解说。
一、四肽化合物TP的制备
本发明式1示四肽化合物TP的制备的反应历程参见前述的式2至式5,其制备方法参见发明内容部分,更详细地制备过程如下:
(一)合成中间化合物3
1.1 Boc-Gly-D-Leu-OBn (3a)
参见上式,把Boc-Gly-OH1(8.75 g,50 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min,使反应液的温度下降到 –15 ℃,加入NMM(6.2 mL,55 mmol),接着把氯甲酸异丁酯(7 mL,55 mmol)缓慢滴加到反应液中。搅拌5 min后,加入事先用无水DMF溶解的D-Leu-OBn2a对甲苯磺酸盐 (19.7 g,50 mmol)和NMM (6.2 mL)的溶液,在 –15oC下继续搅拌反应0.5 h,撤走冰盐浴,自然恢复反应液至室温,反应过夜。待反应结束后,抽滤除去不溶物,滤液减压浓缩,再用乙酸乙酯溶解,乙酸乙酯相依次用1 M NaOH溶液、水、1 M 盐酸溶液和少量饱和食盐水洗涤,无水硫酸钠干燥后,减压浓缩得到Boc-Gly-D-Leu-OBn (3a) 19 g,为淡黄色油状液体,产率100 %. [α]D 20 = + 5.0 (c1.0, CHCl3);1HNMR (200 MHz, CDCl3) δ 7.34 – 7.28 (m, 5H), 6.94 – 6.90 (d,J = 6.8 Hz, 1 H),5.51 (m, 1 H), 5.15 (s, 2H), 4.69 – 4.64 (m, 1 H), 3.83 – 3.81 (m, 2H), 1.62– 1.51 (m, 3H), 1.44(s, 9H), 0.91 – 0.89(m, 6H);13C NMR (100 MHz, CDC13) δ172.6, 169.4, 156.0, 135.3, 128.5, 128.4, 128.2, 128.0, 80.0, 66.9, 50.7,44.1, 41.1, 28.1, 24.7, 22.7, 21.7; ESI-MS calcd for [C20H30N2O5+ H+] 379.2,found: 379.3.。
或者如上式,把Boc-Gly-OH1(8.75 g,50 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min,使反应液的温度下降到 –15 ℃,加入NMM(6.2 mL,55mmol),接着把氯甲酸乙酯(5.3 mL,55 mmol)缓慢滴加到反应液中。搅拌5 min后,加入事先用无水DMF溶解的D-Leu-OBn2a对甲苯磺酸盐 (19.7 g,50 mmol)和NMM (6.2 mL)的溶液,在–15oC下继续搅拌反应半小时,撤走冰盐浴,自然恢复反应液至室温,反应过夜。待反应结束后,抽滤除去不溶物,滤液减压浓缩,再用乙酸乙酯溶解,乙酸乙酯相依次用1 M NaOH溶液、水、1 M 盐酸溶液和少量饱和食盐水洗涤,无水硫酸钠干燥后,减压浓缩得到Boc-Gly-D-Leu-OBn (3a) 17.30 g,为淡黄色油状液体,产率91 %。
或者参见上式,把Boc-Gly-OH1(8.75 g,50 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min,使反应液的温度下降到 –15 ℃,加入NMM(6.2 mL,55mmol),接着把氯甲酸异丙酯(6.3 mL,55 mmol)缓慢滴加到反应液中。搅拌5 min后,加入事先用无水DMF溶解的D-Leu-OBn2a对甲苯磺酸盐 (19.7 g,50 mmol)和NMM (6.2 mL)的溶液,在–15oC下继续搅拌反应0.5 h,撤走冰盐浴,自然恢复反应液至室温,反应过夜。待反应结束后,抽滤除去不溶物,滤液减压浓缩,再用乙酸乙酯溶解,乙酸乙酯相依次用1 M NaOH溶液、水、1 M 盐酸溶液和少量饱和食盐水洗涤,无水硫酸钠干燥后,减压浓缩得到Boc-Gly-D-Leu-OBn (3a) 17.67 g,为淡黄色油状液体,产率93 %。
或者如上式,把Boc-Gly-OH(8.75 g,50 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min,使反应液的温度下降到 –15 ℃,加入TEA(三乙胺,7.6 mL,55mmol),接着把氯甲酸异丁酯(7 mL,55 mmol)缓慢滴加到反应液中。搅拌5 min后,加入事先用无水DMF溶解的D-Leu-OBn对甲苯磺酸盐 (19.7 g,50 mmol)和TEA (7.6 mL)的溶液,在–15oC下继续搅拌反应0.5 h,撤走冰盐浴,自然恢复反应液至室温,反应过夜。待反应结束后,抽滤除去不溶物,滤液减压浓缩,再用乙酸乙酯溶解,乙酸乙酯相依次用1 M NaOH溶液、水、1 M 盐酸溶液和少量饱和食盐水洗涤,无水硫酸钠干燥后,减压浓缩得到Boc-Gly-D-Leu-OBn (3a) 16.48 g,为淡黄色油状液体,产率87%。
或者如上式,把Boc-Gly-OH1(8.75 g,50 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min,使反应液的温度下降到 –15 ℃,加入DIPEA (二异丙基乙胺,9.6 mL,55 mmol),接着把氯甲酸异丁酯(7 mL,55 mmol)缓慢滴加到反应液中。搅拌5min后,加入事先用无水DMF溶解的D-Leu-OBn2a对甲苯磺酸盐 (19.7 g,50 mmol)和DIPEA(9.6 mL)的溶液,在–15oC下继续搅拌反应0.5 h,撤走冰盐浴,自然恢复反应液至室温,反应过夜。待反应结束后,抽滤除去不溶物,滤液减压浓缩,再用乙酸乙酯溶解,乙酸乙酯相依次用1 M NaOH溶液、水、1 M 盐酸溶液和少量饱和食盐水洗涤,无水硫酸钠干燥后,减压浓缩得到Boc-Gly-D-Leu-OBn (3a) 15.47g,为淡黄色油状液体,产率81 %。
1.2 合成Boc-Gly-D-Phe-OBn (3b)
把Boc-Gly-OH1(8.75 g,50 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min,使反应液的温度下降到 -15 ℃,加入NMM(6.2 mL,55 mmol),接着把氯甲酸异丁酯(7 mL,55 mmol)缓慢滴加到反应液中。搅拌5 min后,加入事先用无水DMF溶解的D-Phe-OBn2b的对甲苯磺酸盐 (21.35 g,50 mmol)和NMM (6.2 mL)的溶液,在-15oC下继续搅拌反应0.5 h,撤走冰盐浴,自然恢复反应液至室温反应过夜。待反应结束后,抽滤除去不溶物,滤液减压浓缩,再用乙酸乙酯溶解,乙酸乙酯相依次用1 M NaOH溶液、水、1 M 盐酸溶液和少量饱和食盐水洗涤,无水硫酸钠干燥后,减压浓缩得到淡黄色油状物的Boc-Gly-D-Phe-OBn (3b),石油醚和乙酸乙酯柱层析纯化得到白色固体19.16 g,产率93 %。Whitesolid, Mp 73.5-75oC; [α]D 25= - 11.6 (c0. 5, CHCl3);1H NMR (600 MHz, CDCl3) δ7.35 (m, 3H), 7.30 – 7.27 (m, 1H), 7.23 – 7.18 (m, 2H), 7.13 – 6.86 (m, 2H),6.63 (d,J= 5.7 Hz, 1H), 5.16 - 5.08 (m, 2H), 4.92 (dd,J= 6, 12 Hz, 1H), 3.86– 3.71 (m, 2H), 3.15 – 3.05 (m, 2H), 1.44 (d,J= 8.5 Hz, 9H).13C NMR (150MHz,CDCl3) δ 171.1, 169.1, 135.5, 135.0, 129.3, 128.6, 128.6, 128.5, 128.5,128.4, 128.2, 127.1, 77.2, 77.0, 76.8, 67.3, 53.1, 41.4, 37.9, 28.3(s), 24.8,22.8, 21.8; ESI-MS calcd for [C23H28N2O5 + H+] 413.2, found 413.2.。
(二)合成中间化合物4
2.1 合成NH2-Gly-D-Leu-OBn (4a)
把上面反应得到的二肽Boc-Gly-D-Leu-OBn3a (19 g)溶于50 mL二氯甲烷中,反应液冷却至0 ℃,向其中缓慢滴加TFA(三氟乙酸,50 mL),自然恢复反应溶液至室温下搅拌5 h后,把反应液减压浓缩除去TFA,残留物用二氯甲烷溶解,用1.0 M NaOH 水溶液在0 ℃条件下调 pH = 9.0左右,分离有机相,水相用二氯甲烷(20 mL × 3)萃取。合并有机相,依次用少量饱和食盐水洗涤有机相、无水硫酸钠干燥后,减压浓缩,得到产物NH2-Gly-D-Leu-OBn (4a)为无色油状液体,产率13.25 g (95 %)。无需纯化,直接用于下一步反应。
或者如上式,把上面反应得到的二肽Boc-Gly-D-Leu-OBn 3a (19 g)溶于50 mL二氯甲烷中,反应液冷却至0 ℃,向其中缓慢滴加甲基磺酸(50 mL),自然恢复反应溶液至室温下搅拌5 h后,用1.0 M NaOH 水溶液在0 ℃条件下调 pH = 9.0左右,分离有机相,水相用二氯甲烷(20 mL × 3)萃取。合并有机相,依次用少量饱和食盐水洗涤有机相、无水硫酸钠干燥后,减压浓缩,得到产物NH2-Gly-D-Leu-OBn (4a)为无色油状液体,产率12.83 g(92 %)。无需纯化,直接用于下一步反应。
或者如上式,把上面反应得到的二肽Boc-Gly-D-Leu-OBn 3a (19 g)溶于50 mL二氯甲烷中,反应液冷却至0 ℃,向其中缓慢滴加三氟甲磺酸 (50 mL),自然恢复反应溶液至室温下搅拌5 h后,用1.0 M NaOH 水溶液在0 ℃条件下调 pH = 9.0左右,分离有机相,水相用二氯甲烷(20 mL × 3)萃取。合并有机相,依次用少量饱和食盐水洗涤有机相、无水硫酸钠干燥后,减压浓缩,得到产物NH2-Gly-D-Leu-OBn (4a) 为无色油状液体,产率12.7 g(91 %)。无需纯化,直接用于下一步反应。
2.2 合成H2N-Gly-D-Phe-OBn (4b)
把上面反应得到的二肽Boc-Gly-D-Phe-OBn3b (18.2 g, 44 mmol) 溶于44 mL二氯甲烷中,反应液冷却至0 ℃,向其中缓慢滴加TFA (44 mL),自然恢复反应溶液至室温下搅拌5 h后,把反应液减压浓缩除去TFA,残留物用二氯甲烷溶解,用1M NaOH 水溶液在0 ℃条件下调 pH = 9.0左右,分离有机相,水相用二氯甲烷(20 mL × 3)萃取。合并有机相,依次用少量饱和食盐水洗涤有机相、无水硫酸钠干燥后,减压浓缩,得到产物NH2-Gly-D-Leu-OBn (4b)为无色油状液体,产率12.5 g (91 %)。无需纯化,直接用于下一步反应。
(三)中间化合物6的合成
3.1 合成Boc-Pro-Gly-D-Leu-OBn (6a)
将Boc-Pro-OH5(9.68 g,45 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min使反应液的温度下降到 –15 ℃,加入NMM(5.6 mL,50 mmol),把氯甲酸异丁酯(6.4 mL,50 mmol)缓慢滴加到反应液中,搅拌5 min后,加入预先用无水THF溶解的二肽NH2-Gly-D-Leu-OBn4a(12.56 g,45 mmol)和NMM (5.6 mL)的溶液。冰盐浴下继续搅拌30min,撤走冰盐浴,使反应自然恢复至室温,反应搅拌过夜至反应结束,抽滤出去不溶物,滤液减压浓缩,残余油状物用乙酸乙酯溶解,然后依次用1.0 M NaOH溶液、水、1.0 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,得到淡黄色油状液体的Boc-Pro-Gly-D-Leu-OBn (6a),用石油醚和乙酸乙酯柱层析纯化得到20.33 g产物,产率95 %。Whitesolid, Mp: 104–105 ℃; [α]D 20 = - 27 (c1.0, CHCl3);1HNMR (400 MHz, CDCl3) δ7.38 – 7.32 (m, 5H), 7.22 (br, 1H), 7.03 (br, 1H), 5.08 – 5.07 (dd,J =12.8Hz,J = 21.6 Hz, 2H), 4.57 – 4.55 (m, 1H), 4.25 – 4.11 (m, 2H), 3.86 –3.81 (dd,J = 4.8 Hz,J = 17.2 Hz, 1H), 3.50 – 3.40 (m, 2H), 2.15 – 2.11 (m,2H), 1.92 – 1.89 (m, 2H), 1.60 – 1.73(m, 3H), 1.44 (s, 9H), 0.92 – 0.89 (m,6H);13C NMR (100 MHz, CDCl3) δ 172.5, 169.3, 155.8, 128.5, 128.1, 128.0,109.7, 80.8, 66.7, 60.9, 51.0, 47.4, 42.8, 40.1, 29.5, 28.3, 24.7, 24.6,22.8, 21.5; ESI-MS calcd for [C25H37N3O6 + H+] 476.3, found: 476.3.。
3.2 合成Boc-Pro-Gly-D-Phe-OBn (6b)
将Boc-Pro-OH5(7.53 g,35 mmol)加入到100 mL的无水THF中,氩气保护下在冰盐浴中搅拌5 min使反应液的温度下降到 -15 ℃,加入NMM(4.3 mL,38.5 mmol),把氯甲酸异丁酯(4.9 mL,38.5 mmol)缓慢滴加到反应液中,搅拌5 min后,加入预先用无水THF溶解的二肽 NH2-Gly-D-Phe-OBn4b(10.92 g,35 mmol)和NMM (4.3 mL)的溶液。冰盐浴下继续搅拌30 min,撤走冰盐浴,使反应自然恢复至室温,反应搅拌过夜至反应结束,抽滤出去不溶物,滤液减压浓缩,残余油状物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩用石油醚和乙酸乙酯柱层析纯化得到Boc-Pro-Gly-D-Phe-OBn (6b)产物,17.1 g,产率96 %。White solid, Mp 100-102oC;[α]D 25= - 66.0 (c0. 5, CHCl3);1H NMR (600 MHz, CDCl3) δ 7.34 (d,J= 6.5 Hz, 2H),7.27 (s, 1H), 7.21 (t,J= 7.3 Hz, 2H), 7.13 – 6.89 (m, 3H), 6.54 (m, 1H), 5.12(t,J= 14.8 Hz, 2H), 4.84 (s, 1H), 4.22 (s, 1H), 3.92 (d,J= 33.6 Hz, 2H), 3.51– 3.33 (m, 2H), 3.17 - 3.05 (m, 2H), 2.23 – 2.00 (m, 2H), 1.86 (s, 2H), 1.45(s, 9H).13C NMR (150 MHz, CDCl3) δ 172.5, 171.1, 168.8, 136.1, 135.3, 129.3,129.2, 128.6,128.5,128.4, 127.0, 80.7, 77.3, 77.0, 76.8, 67.1, 60.6, 53.6,47.32, 43.0, 37.6, 28.4, 24.6; ESI-MS calcd for [C28H35N3O6 + H+] 510.2, found510.2.。
(四)中间化合物7的合成
4.1 合成NH2-Pro-Gly-D-Leu-OBn (7a)
将合成的三肽Boc-Pro-Gly-D-Leu-OBn6a(19 g,40 mmol)完全溶于CH2Cl2(40 mL)中,在0 ℃下缓慢滴加TFA(40 mL),恢复反应液至室温下,搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 9.0左右。分离出有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,饱和食盐水洗一次,无水硫酸钠干燥,减压浓缩,得到13.54 g 无色油状液体的NH2-Pro-Gly-D-Leu-OBn (7a),产率为 90 %,无需纯化,直接用于下一步反应。
4.2合成Pro-Gly-D-Phe-OBn (7b)
将合成的三肽Boc-Pro-Gly-D-Phe-OBn6b(16.5 g, 32 mmol)完全溶于CH2Cl2(32mL)中,在0 ℃下缓慢滴加TFA(32 mL),恢复反应液至室温下,搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 9.0左右。分离出有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,饱和食盐水洗一次,无水硫酸钠干燥,减压浓缩,得到11.8 g 无色油状液体的Pro-Gly-D-Phe-OBn (7b),产率为 90 %。无需纯化,直接用于下一步反应。
(五)中间化合物9的合成
5.1 合成Boc-D-Val-Pro-Gly-D-Leu-OBn (9a)
把HOBt (4.45 g, 33 mmol),Boc-D-Val-OH8a( 6.45 g,30 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入60 mL干燥的THF,0 ℃搅拌待瓶内温度降至0 ℃ 时,缓慢滴加DIC(N,N'-二异丙基碳二亚胺,5.1 mL,33 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Leu-OBn7a(11.28 g, 30 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩后用石油醚和乙酸乙酯柱层析纯化,得到14.84g 白色固体四肽Boc-D-Val-Pro-Gly-D-Leu-OBn (9a),产率86 %。White solid,Mp: 123.5–125.5oC;[α]D 20 = + 15 (c0.7, CHCl3);1H NMR (400 MHz, CDCl3) δ 7.36 – 7.30 (m, 5H), 7.24– 7.23 (m, 1 H), 5.34 – 5.32 (d,J = 6.8 Hz, 1 H), 5.20 – 5.13 (dd,J= 12.4 Hz,J = 14.8 Hz, 2H), 4.64 – 4.59 (m, 1H), 4.50 – 4.50 (t,J = 6.0 Hz, l H), 4.20– 4.14 (dd,J = 7.2 Hz,J = 16.8 Hz, 1 H), 4.07 (m, 1 H), 3.98 – 3.94 (m, 1 H),3.65 – 3.56 (m, 2H), 2.21 – 2.16 (m, 2H), 2.09 – 1.99 (m, 2H), 1.95 – 1.90(m, 1 H), 1.76 – 1.61 (m, 3H), 1.40 (s, 9H), 1.01 – 1.00 (d,J = 6.8 Hz, 3H),0.97 – 0.95 (d,J = 6.8 Hz, 3H), 0.92 – 0.88 (m, 6H);13C NMR (100 MHz, CDCl3) δ172.6, 171.7, 169.0, 156.9,135.7, 128.4, 128.0, 127.8, 80.3, 66.4, 61.0,58.2, 50.7, 47.6, 43.1, 40.7, 30.1, 29.2, 28.1, 24.6, 23.4, 22.8, 21.7, 19.1,18.8; ESI-MS calcd for [C30H46N4O7+H+] 575.3, found 575.3.。
或者如上式示,把HOBt (4.45 g, 33 mmol),Boc-D-Val-OH8a(6.51 g,30 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入60 mL干燥的THF,0 ℃搅拌待瓶内温度降至0℃ 时,缓慢滴加用DMF溶解的DCC(N,N'-二环己基碳二亚胺,6.8 g,33 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Leu-OBn7a(11.28 g, 30 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩后用石油醚和乙酸乙酯柱层析纯化,得到12.42 g 白色固体四肽Boc-D-Val-Pro-Gly-D-Leu-OBn (9a),产率72 %。
5.2合成Boc-D-Tle-Pro-Gly-D-Leu-OBn (9b)
把HOBt (4.45 g, 33 mmol),Boc-D-Tle-OH8b(6.93 g,30 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入60 mL干燥的THF,0 ℃搅拌待瓶内温度降至0 ℃ 时,缓慢滴加DIC(5.1 mL,33 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Leu-OBn7a(11.28 g, 30 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩后用石油醚和乙酸乙酯柱层析纯化,得到15.02 g白色固体的四肽Boc-D-Tle-Pro-Gly-D- Leu-OBn (9b),产率85 %。White solid, Mp 168–169.4oC; [α]D 25 = + 9.0 (c0.5, CHCl3);1H NMR (600 MHz, CDCl3) δ 7.47 (d,J= 7.7 Hz, 1H), 7.35 (d,J= 4.4 Hz,3H), 7.33 – 7.28 (m, 1H), 7.08 – 7.03 (m, 1H), 5.48 (d,J= 7.1 Hz, 1H), 5.19 –5.12 (m, 2H), 4.62-4.55 (m, 1H), 4.46 (dd,J= 7.5, 4.9 Hz, 1H), 4.22 (dd,J=17.2, 7.9 Hz, 1H), 4.15 – 4.10 (m, 1H), 4.07 (d,J= 7.1 Hz, 1H), 3.65 – 3.59(m, 1H), 3.56 (dd,J= 17.1, 5.1 Hz, 1H), 2.20 – 2.15 (m, 2H), 2.09 – 2.03 (m,1H), 2.00 (dd,J= 11.3, 5.3 Hz, 1H), 1.77 – 1.56 (m, 4H), 1.40 (s, 9H), 1.04(s, 9H), 0.88 (dd,J= 12.8, 6.4 Hz, 6H).13C NMR (150 MHz, CDCl3) δ 172.7,172.2, 171.7, 169.1, 135.91, 128.5, 128.1,128.0, 77.24, 77.0, 76.8, 66.4,61.3, 59.7, 50.9, 48.3, 43.2, 40.7, 33.9, 29.4, 28.2, 26.5, 24.8, 24.7, 22.8,21.8; ESI-MS calcd for [C31H48N4O7 + H+] 588.7, found 588.7.。
5.3合成Boc-D-Phg-Pro-Gly-D-Leu-OBn (9c)
把HOBt (4.45 g, 33 mmol),Boc-D-Phg-OH8c(7.53 g,30 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入60 mL干燥的THF,0 ℃搅拌待瓶内温度降至0 ℃ 时,缓慢滴加DIC(5.1 mL,33 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Leu-OBn7a(11.28 g, 30 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,得到15.52 g四肽Boc-D-Phg-Pro-Gly-D-Leu-OBn (9c),产率85 %。White solid, Mp142–144oC; [α]D 25 = - 2.0 (c0. 5, CHCl3);1H NMR (600 MHz, CDCl3) δ 7.45 – 7.39(m, 2H), 7.38 – 7.32 (m, 6H), 7.27 (s, 1H), 7.22 (d,J= 7.0 Hz, 1H), 5.72 (d,J=5.2 Hz, 2H), 5.38-5.30 (m, 1H), 5.17 (d,J= 3.3 Hz, 2H), 4.66 – 4.61 (m, 1H),4.47 – 4.39 (m, 1H), 4.04 (dd,J= 16.8, 6.6 Hz, 1H), 3.98– 3.94 (m, 1H), 3.83(dd,J= 12.7, 6.3 Hz, 1H), 3.38 – 3.29 (m, 1H), 2.21 – 2.16 (m, 1H), 2.09–1.99 (m, 2H), 1.75 – 1.70 (m, 2H), 1.39 (d,J= 4.9 Hz, 9H), 1.13 (d,J= 6.5 Hz,4H), 0.96 – 0.90 (m, 6H).13C NMR (150 MHz, CDCl3) δ 172.5, 171.5, 169.0,135.7, 129.2, 129.1, 128.5, 128.4, 128.1 (dd,J= 12.3, 9.2 Hz), 80.5, 77.2,77.0, 76.8, 66.8, 61.2, 51.0, 47.3, 43.4, 42.1, 41.1, 28.2, 24.6, 23.4, 22.8,21.8; ESI-MS calcd for [C33H44N4O7 + H+] 609.3, found 609.3。
5.4合成四肽Boc-D-Chg-Phe-Pro-Gly-D-Leu-OBn (9d)
把HOBt (4.45 g, 33 mmol),Boc-D-Chg-OH8d(7.71 g,30 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入60 mL干燥的THF,0 ℃搅拌待瓶内温度降至0 ℃ 时,缓慢滴加DIC(5.1 mL,33 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Leu-OBn7a(11.28 g, 30 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,石油醚和乙酸乙酯柱层析纯化得到四肽Boc-D-Chg-Phe-Pro-Gly-D-Leu-OBn (9d)15.5 g,产率84 %。White solid, Mp: 160–161oC; [α]D 20 = - 10 (c0.62, CHCl3);1H NMR(400 MHz, CDCl3)δ 7.37 – 7.30 (m, 5H), 5.28 – 5.26 (d,J = 6.4 Hz, 1 H), 5.21 –5.13 (m, 2H), 4.66 – 4.60 (m, 1H), 4.50 – 4.47 (m, 1H), 4.20 – 4.07 (m, 2H),4.00 – 3.96 (m, 1H), 3.64 – 3.56 (m, 2H), 2.21 – 2.16 (m, 2H), 2.10 – 1.98(m, 2H), 1.87 – 1.84 (m, 1H), 1.79 – 1.56 (m, 8H), 1.39 (s, 9H), 1.28 – 1.17(m, 4H), 1.31 – 1.11 (d,J = 6.8 Hz, 2H), 1.06 – 0.99 (m, 2H), 0.92 – 0.89 (m,6H);13C NMR (100 MHz, CDCl3) δ 172.5, 171.7, 169.0, 157.0, 135.7, 128.4,128.0, 127.8, 80.3, 66.3, 60.9, 57.6, 50.7, 47.6, 43.1, 41.8, 40.8, 39.5,29.4, 29.2, 28.1, 26.0, 25.7, 25.6, 24.6, 23.4, 22.8, 21.7; ESI-MS calcd for[C33H50N4O7+ H+] 614.4, found: 614.4.。
5.5合成Boc-D-Phe-Pro-Gly-D-Leu-OBn (9e)
把HOBt (4.45 g, 33 mmol),Boc-D-Phe-OH8e(7.95 g,30 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入60 mL干燥的THF,0 ℃搅拌待瓶内温度降至0 ℃ 时,缓慢滴加DIC(5.1 mL,33 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Leu-OBn7a(11.28 g, 30 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,石油醚和乙酸乙酯柱层析纯化得到四肽Boc-D-Phe-Pro-Gly-D-Leu-OBn (9e),16.07g, 产率86 %。White solid, Mp:160-161 ℃; [α]D 20 = - 10 (c 0.62, CHCl3);1H NMR(400 MHz, CDCl3) δ 7.40 - 7.19 (m, 10H), 5.50 (br, 1H), 5.18 (s, 1H), 4.65 -4.64 (m, 1 H), 4.41 - 4.38 (m, 1H), 4.32 - 4.30 (m, 1H), 4.16 - 4.10 (m, 1H),3.69 - 3.61 (m, 2H), 2.68 - 2.65 (m, 1H), 2.05 - 2.02 (m, 1H), 1.91 - 1.56(m, 8H), 1.39 (s, 9H), 1.14 - 1.12 (m, 2H), 0.96 - 0.91 (m, 6H);13C NMR (100MHz, CDCl3) δ 172.6, 172.0, 171.5, 169.0 156.3,135.9, 135.7, 129.2, 128.6,128.5, 128.1,127.9, 127.2, 80.5, 66.5, 60.9, 54.4, 50.7, 47.1, 43.1, 42.0,40.9, 3 8.1, 28.8, 28.1, 24.6, 24.4, 23.4, 22.9, 21.7; ESI-MS calcd for[C34H46N4O7+H+] 623.3, found 623.3.。
5.6 合成Boc-D-Phe-Pro-Gly-D-Phe-OBn (9f)
把HOBt (3.71g, 27.5 mmol),Boc-D-Phe-OH8e(6.63,25 mmol)加入到150 mL的圆底烧瓶中,氩气保护,加入50 mL干燥的THF,0 ℃搅拌待瓶内温度降至0 ℃ 时,缓慢滴加DIC(4.25 mL,27.5 mmol),0.5 h之后加入事先用THF溶解好的三肽Pro-Gly-D-Phe-OBn7b(10.23g, 25 mmol)。室温搅拌48 h后滤去不溶物,滤液减压浓缩干。残留物用乙酸乙酯溶解,然后依次用1 M NaOH溶液、水、1 M 盐酸溶液和饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩后用石油醚和乙酸乙酯柱层析纯化得到四肽Boc-D-Phe-Pro-Gly-D-Phe-OBn (9f),13.45g,产率82 %。White solid, Mp 138-139.6oC; [α]D 25= - 49.0 (c0.5, CHCl3);1HNMR (600 MHz, CDCl3) δ 7.33 – 7.28 (m, 4H), 7.25 – 7.18 (m, 8H), 7.16 – 7.13(m, 3H), 5.45 (d,J= 6.5 Hz, 1H), 5.13 – 5.08 (m, 2H), 4.88 (dd,J= 14.4, 6.6Hz, 1H), 4.46 – 4.41 (m, 1H), 4.33 (dd,J= 7.8, 3.7 Hz, 1H), 3.98 (dd,J= 17.0,6.9 Hz, 1H), 3.73 (dd,J= 17.0, 5.7 Hz, 1H), 3.66 – 3.585 (b, 1H), 3.15 (dd,J=6.7, 2.6 Hz, 2H), 2.95 (t,J= 7.7 Hz, 2H), 2.67 (dd,J= 16.8, 7.6 Hz, 1H), 2.08– 2.02 (m, 1H), 1.84 – 1.75 (b, 3H), 1.57 – 1.51 (b, 1H), 1.39 (s, 9H).13C NMR(150 MHz, CDCl3) δ 171.9, 171.5, 171.4, 168.8, 136.2, 135.4, 129.4, 129.3,128.6, 128.5, 128.4, 128.3, 128.2, 127.2, 126.8, 80.5, 77.2, 77.0, 76.8,66.9, 60.8, 53.6, 47.1, 43.2, 38.2, 28.7, 28.3, 24.4; ESI-MS calcd for[C37H44N4O7 + H+] 657.3, found 657.3.。
(六)中间化合物10的合成
6.1 合成H2N-D-Val-Pro-Gly-D-Leu-OBn (10a)
把前面合成的四肽Boc-D-Val-Pro-Gly-D-Leu-OBn9a(12.65g, 22 mmol)溶于CH2Cl2(20mL)中,然后在0 ℃下缓慢滴加TFA(20 mL),室温下搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 9.0左右。分离有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,饱和食盐水洗一次,无水硫酸钠干燥,减压浓缩,得到10.03 g无色油状液体的H2N-D-Val-Pro-Gly-D-Leu-OBn (10a),产率为96 %。无需纯化,直接用于下一步反应。
6.2 合成H2N-D-Tle-Pro-Gly-D-Leu-OBn (10b)
把前面合成的四肽Boc-D-Tle-Pro-Gly-D-Leu-OBn9b(12.96 g, 22 mmol)溶于CH2Cl2(25 mL)中,然后在0 ℃下缓慢滴加TFA (25 mL),室温下搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 9.0左右。分离有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,饱和食盐水洗一次,无水硫酸钠干燥,减压浓缩,得到10.22 g无色油状液体的H2N-D-Tle-Pro-Gly-D-Leu-OBn (10b),产率为95 %。无需纯化,直接用于下一步反应。
6.3 合成H2N-D-Phg-Pro-Gly-D-Leu-OBn (10c)
/>
把前面合成的四肽Boc-D-Phg-Pro-Gly-D-Leu-OBn9c (13.4 g, 22 mmol)溶于CH2Cl2 (25 mL)中,然后在0 ℃下缓慢滴加TFA(25 mL),室温下搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 9.0左右。分离有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,饱和食盐水洗一次,无水硫酸钠干燥,减压浓缩,得到10.3 g无色油状液体的H2N-D-Phg-Pro-Gly-D-Leu-OBn (10c),产率为92 %。无需纯化,直接用于下一步反应。
6.4 合成四肽H2N-D-Chg -Pro-Gly-D-Leu-OBn (10d)
把前面合成的四肽Boc-D-Chg-Pro-Gly-D-Leu-OBn9d(13.53 g, 22 mmol)溶于CH2Cl2(25 mL)中,然后在0 ℃下缓慢滴加TFA(25 mL),室温下搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 11.0左右。分离有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,依次用饱和食盐水洗涤、无水硫酸钠干燥,减压浓缩,得到无色油状液体的H2N-D-Chg-Pro-Gly-D-Leu-OBn (10d) 10.6g,产率为94 %。无需纯化,直接用于下一步反应。
6.5 合成H2N-D-Phe-Pro-Gly-D-Leu-OBn (10e)
把前面合成的四肽Boc-D-Phe-Pro-Gly-D-Leu-OBn9e(13.7 g, 22 mmol)溶于CH2Cl2(25 mL)中,然后在0 ℃下缓慢滴加TFA(25 mL),室温下搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 9.0左右。分离有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,依次用饱和食盐水洗涤、无水硫酸钠干燥,减压浓缩,得到无色油状液体的H2N-D-Phe-Pro-Gly-D-Leu-OBn (10e),10.5 g,产率为91 %。无需纯化,直接用于下一步反应。
6.6 合成H2N-D-Phe-Pro-Gly-D-Phe-OBn (10f)
把前面合成的四肽Boc-D-Phe-Pro-Gly-D-Phe-OBn9f(13.12 g, 20 mmol)溶于CH2Cl2(25 mL)中,然后在0 ℃下缓慢滴加TFA(25 mL),室温下搅拌5 h。将反应液减压浓缩尽量除去TFA,残留物用CH2Cl2溶解,再用1 M NaOH 溶液在0 ℃下中和至约 pH = 11.0左右。分离有机相,水相用CH2Cl2(20 mL ×3)萃取。合并有机相,饱和食盐水洗一次,无水硫酸钠干燥,减压浓缩,得到10.62 g无色油状液体的H2N-D-Phe-Pro-Gly-D-Phe-OBn (10f),产率为94 %。无需纯化,直接用于下一步反应。
以下是本发明的TP-1至TP-6具体化合物的制备方法。
实施例1
合成四肽TP-1:NH2-D-Val-Pro-Gly-D-Leu-OH
把前面合成的NH2-D-Val-Pro-Gly-D-Leu-OBn10a (10.0 g, 21 mmol)溶于甲醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8Mpa,搅拌6小时。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Val-Pro-Gly-D-Leu-OH (TP-1),8.0 g,产率100 %。White solid ,Mp: 152–154 ℃;[α]D 20= – 58.0 (c 0.85,H2O);1H NMR (600 MHz, D2O) δ 4.55 – 4.50 (m, 1H), 4.31 – 4.25 (m, 1H), 4.04(d,J= 17.1 Hz, 1H), 3.90 (d,J= 17.1 Hz, 1H), 3.87-3.83 (m, 1H), 3.77-3.73 (m,1H), 2.41 – 2.33 (m,2H), 2.11-2.04 (m, 3H), 1.74 – 1.60 (m, 4H), 1.13 (d,J=7.2 Hz ,3H), 1.05 (d,J= 12 Hz ,3H), 0.95 (d,J= 6 Hz 3H), 0.91 (d,J= 6 Hz,3H).13C NMR (150 MHz, D2O) δ 179.7, 174.3, 170.4, 168.9, 61.1, 57.1, 53.5, 48.1,42.4, 40.5, 29.2, 28.7, 24.5, 24.3, 22.4, 20.5, 17.9, 15.9; HRMS calcd for[C18H32N4O5+ H+] 385.2445, found 385.2438.
或者把前面合成的NH2-D-Val-Pro-Gly-D-Leu-OBn(10.0 g)溶于乙醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8 Mpa,搅拌6小时。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Val-Pro-Gly-D-Leu-OH (TP-1),为白色固体,7.45 g,产率93%。
实施例2
合成TP-2:H2N-D-Tle-Pro-Gly-D-Leu-OH
把前面合成的NH2-D-Tle-Pro-Gly-D-Leu-OBn10b (10.0 g, 20 mmol)溶于甲醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8Mpa,搅拌6小时。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Tle-Pro-Gly-D-Leu-OH (TP-2),7.8 g,产率98 %。White solid,Mp:204–205 ℃, [α]D 20 = – 28.0 (c1.0,DMF);1H NMR (600 MHz, D2O) 4.38 – 4.34 (m, 1H), 4.12 – 4.02 (m, 2H), 3.81 (q,J= 17.1 Hz, 2H), 3.72 – 3.63 (m, 2H), 3.21 (d,J= 0.4 Hz, 1H), 2.24 – 2.18 (m,1H), 1.91 (s, 3H), 1.57 – 1.52 (m, 1H), 1.50 – 1.42 (m, 2H), 0.97 (s, 9H),0.76 (dd,J= 22.8, 5.8 Hz, 6H);13C NMR (150 MHz, D2O) δ 179.8, 174.3, 170.4,168.2, 61.0, 59.1, 53.7, 49.0, 42.4, 40.6, 33.9, 29.3, 25.3, 24.5, 24.26,22.4, 20.5; HRMS calcd for [C19H30N4O5+ H+] 399.2602, found 399.2599。
实施例3
合成TP-3:H2N-D-Phg-Pro-Gly-D-Leu-OH
/>
把前面合成的NH2-D-Phg-Pro-Gly-D-Leu-OBn10c (10.0 g, 19.5 mmol)溶于甲醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8 Mpa,搅拌6 h。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Phg-Pro-Gly-D-Leu-OH (TP-3),7.8 g,产率96 %。 White solid,Mp: 150– 153 ℃, [α]D 20 = – 94.0(c1.0, H2O);1H NMR (600 MHz, D2O) δ 7.62 – 7.42 (m, 5H), 5.47 (s, 1H), 4.50(dd,J= 9.0, 3.8 Hz, 1H), 4.31 (dd,J= 10.6, 3.2 Hz, 1H), 4.09 (d,J= 17.2 Hz,1H), 3.89 (d,J= 17.2 Hz, 1H), 3.80 – 3.71 (m, 1H), 3.07 – 3.00 (m, 1H), 2.25– 2.15 (m, 1H), 2.05 – 1.94 (m, 2H), 1.86 – 1.72 (m, 2H), 1.69 – 1.53 (m,2H), 1.01 – 0.86 (m, 6H);13C NMR (150 MHz, D2O) δ 179.9, 174.3, 170.3, 167.4,130.6, 129.8, 129.6, 128.9, 128.5, 61.5, 56.4, 53.6, 47.5, 42.3, 40.6, 28.9,24.6, 24.2, 22.4, 20.6;HRMS calcd for [C21H30N4O5+ H+] 419.2289, found:419.2285.。
实施例4
合成TP-4:H2N-D-Chg-Pro-Gly-D-Leu-OH
把前面合成的NH2-D-Chg-Pro-Gly-D-Leu-OBn10d (10.0 g,19.4 mmol)溶于甲醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8Mpa,搅拌6小时。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Chg-Pro-Gly-D-Leu-OH (TP-4), 7.94 g,产率97 %。White solid,Mp: 167–169 ℃, [α]D 20 = – 96.0 (c1.0,H2O);1H NMR (600 MHz, D2O) δ 4.55 – 4.46 (m, 1H), 4.33 – 4.20 (m, 2H), 4.03(d,J= 17.1 Hz, 1H), 3.93 – 3.70 (m, 3H), 2.40 – 2.32. (m, 1H), 2.13 – 1.94(m, 3H), 1.86 – 1.57 (m, 7H), 1.37 – 1.07 (m, 5H), 0.98 – 0.86 (m, 6H);13C NMR(150 MHz, D2O) δ 179.6, 174.3, 170.4, 168.8, 61.1 , 56.6, 53.9, 53.4, 48.1,42.4, 40.5, 38.4, 29.3, 28.5, 27.1, 25.1 , 24.5, 24.2, 22.4, 20.5; HRMS calcdfor [C21H36N4O5+ H+] 425.2758, found 425.2748.。
实施例5
合成TP-5:NH2-D-Phe-Pro-Gly-D-Leu-OH
把前面合成的NH2-D-Phe-Pro-Gly-D-Leu-OBn9e(10.0 g,19.1 mmol)溶于甲醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8Mpa,搅拌6小时。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Phe-Pro-Gly-D-Leu-OH (TP-5),为白色固体,7.7 g,产率93 %。White solid , Mp: 198-200 ℃; [α]D 20 = –98.0 (c1.0, H2O);1H NMR (600 MHz, D2O) 7.45 - 7.39 (m, 3H), 7.35 (d,J= 6.9 Hz,2H), 4.62 - 4.57 (m, 1H), 4.37 (dd,J= 8.8, 4.6 Hz, 1H), 4.26 (dd,J= 10.5, 3.5Hz, 1H), 4.01 (d,J= 17.1 Hz, 1H), 3.88 (d,J= 17.2 Hz, 1H), 3.64 – 3.57 (m,1H), 3.30 - 3.18 (m, 2H), 2.86 - 2.80(m, 1H), 2.16 – 2.08 (m, 1H), 1.97 -1.85 (m, 2H), 1.73 – 1.56 (m, 4H), 0.92 (dd,J= 28.0, 6.0 Hz, 6H);13C NMR (150MHz, D2O) δ 179.8, 174.1, 170.3, 168.5, 133.3, 129.4, 129.1, 128.1, 61.0,53.6, 53.0, 47.7, 42.4, 40.5, 36.3, 29.1, 24.5, 24.0, 22.4, 20.5; HRMS calcdfor [C22H32N4O5+ H+] 433.2445, found 419.2439.。
实施例6
合成TP-6:NH2-D-Phe-Pro-Gly-D-Phe-OH
把前面合成的NH2-D-Phe-Pro-Gly-D-Phe-OBn10f(10.2 g, 18 mmol)溶于甲醇(20 mL),转移到100 mL的高压反应釜中,然后加入500 mg Pd/C(5 %)。室温下通入氢气至8Mpa,搅拌6小时。过滤除去Pd/C,滤液减压浓缩,得到产物四肽NH2-D-Phe-Pro-Gly-D-Phe-OH (TP-6),为白色固体,7.8 g,产率92 %。Mp 182.5–184.4 ℃, [α]D 20 = – 50.0 (c 0.5,DMF);1H NMR (600 MHz, DMSO) δ 8.50 – 8.16 (m, 2H), 7.41 – 7.03 (m, 10H), 4.38(m, 3H), 3.76 – 3.64 (m, 1H), 3.50 – 3.32 (m, 2H), 3.20 – 2.79 (m, 4H), 1.87– 1.60 (m, 3H), 1.40 – 1.26 (m, 1H), 0.98 (d,J= 6.5 Hz, 1H);13C NMR (150 MHz,DMSO) δ 175.0, 171.4, 170.2, 168.3, 139.3, 136.0, 129.9, 129.7, 128.9, 128.3,127.5, 126.2, 61.2, 52.9, 47.1, 42.1, 40.4 , 40.2, 40.1, 39.9, 39.7, 39.6,38.8, 29.3, 24.4, 23.7; HRMS calcd for [C25H30N4O5+ H+] 467.2288, found:467.2289.。
二、化合物TP的应用例
实施例7
在洁净的5 mL圆底烧瓶中加入准确称量的本发明的四肽催化剂TP(0.025 mmol)、N-苯基马来酰亚胺(87 mg, 0.5 mmol)和1.0 mL干燥重蒸过的甲苯,在冰水浴和磁力搅拌条件下加入重蒸的异丁醛(92 µL, 1.0 mmol),恢复反应液至室温下继续搅拌反应,通过TLC检测至反应结束后,加3~4滴饱和氯化铵溶液,用乙酸乙酯萃取(10 mL × 3),少量饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,残余油状物利用石油醚和乙酸乙酯柱层析纯化,获得纯产物。
本发明的TP-1~TP-6六种四肽催化剂催化异丁醛与N-苯基马来酰亚胺的不对称共轭加成反应的评价,结果如下表1所示。由结果可知,TP-3和TP-5的不对称催化效率最高。
实施例8.
溶剂对四肽TP-5催化异丁醛与N-苯基马来酰亚胺不对称共轭加成反应的影响。
在洁净的5 mL圆底烧瓶中加入准确称量的四肽催化剂TP-5(0.025 mmol,10.8mg)、N-苯基马来酰亚胺(87 mg, 0.5 mmol)和1.0 mL干燥重蒸过的反应溶剂,在冰水浴下和磁力搅拌条件下加入重蒸的异丁醛(92 µL, 1.0 mmol),恢复反应液至室温下继续搅拌反应,通过TLC检测至反应结束后,加3~4滴饱和氯化铵溶液,用乙酸乙酯萃取(10 mL ×3),少量饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,残余油状物利用石油醚和乙酸乙酯柱层析纯化,获得纯产物。
各种溶剂对反应的产率和ee值影响,结果见下表2所示。结果显示:与甲苯相比较,乙腈为溶剂时产率和ee值都显著提高。
实施例9.
观察催化剂用量对不对称共轭加成反应的催化效率的影响。
在洁净的5 mL圆底烧瓶中加入准确称量的四肽催化剂TP-5或TP-3(0.025 mmol)、N-苯基马来酰亚胺(87 mg, 0.5 mmol)和1.0 mL干燥重蒸过的反应溶剂,在冰水浴下和磁力搅拌条件下加入重蒸的异丁醛(92 µL, 1.0 mmol),恢复反应液至室温下继续搅拌反应,通过TLC检测至反应结束后,加3~4滴饱和氯化铵溶液,用乙酸乙酯萃取(10 mL × 3),少量饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,残余油状物利用石油醚和乙酸乙酯柱层析纯化,获得纯产物。
反应产率和ee值如下表3所示。结果显示,使用2.5 mol%用量的TP-3四肽为催化剂,以乙腈为溶剂,可以获得最优的不对称催化效果。
实施例10
观察四肽TP-3催化脂肪醛与马来酰亚胺不对称共轭加成反应的底物适应范围。
在洁净的5 mL圆底烧瓶中加入准确称量的四肽催化剂2.5%TP-3(0.0125 mmol,5.3 mg)、马来酰亚胺(0.5 mmol)和1.0 mL干燥重蒸过的乙腈,在冰水浴下和磁力搅拌条件下加入重蒸的脂肪醛(1.0 mmol),恢复反应液至室温下继续搅拌反应,通过TLC检测至反应结束后,加3~4滴饱和氯化铵溶液,用乙酸乙酯萃取(10 mL × 3),少量饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,残余油状物利用石油醚和乙酸乙酯柱层析纯化,获得纯产物。
结果如表4所示。
表4. 四肽TP-3催化的脂肪醛与马来酰亚胺的不对称共轭加成反应.
a 分离产率,ee由手性HPLC确定。
产物P-1~P-17表征如下。
P-1, [α]D 25= -6.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.51 (s, 1H), 7.48-7.44 (m, 2H), 7.40 – 7.36 (m, 1H), 7.29-7.25 (m,2H), 3.14 (dd,J= 9.6, 5.6 Hz, 1H), 2.96 (dd,J= 18.6, 9.6 Hz, 1H), 2.61 (dd,J=18.4, 5.6 Hz, 1H), 1.32 (s, 3H), 1.28 (s, 3H).。
P-2, [α]D 25= +2.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.49 (s, 1H), 7.28 – 7.24 (m, 2H), 7.17-7.12 (m, 2H), 3.11 (dd,J=9.6, 5.6 Hz, 1H), 2.97 (dd,J= 18.3, 9.6 Hz, 1H), 2.61 (dd,J= 18.4, 5.6 Hz,1H), 1.35 (s, 3H), 1.28 (s, 3H).。
P-3, [α]D 25 = +3.0 (c= 1.0, CHCl3);1H NMR (600MHz, CDCl3) δ 9.49 (s, 1H), 7.49 – 7.40 (m, 2H), 7.28 – 7.22 (m, 2H), 3.11(dd,J= 9.6, 5.6 Hz, 1H), 2.97 (dd,J= 18.3, 9.6 Hz, 1H), 2.62 (dd,J= 18.3, 5.6Hz, 1H), 1.36 (s, 3H), 1.29 (s, 3H).。
P-4, [α]D 25= +3.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.49 (s, 1H), 7.62 – 7.57 (m, 1H), 7.23 – 7.15 (m, 2H), 3.11 (dd,J=9.6, 5.4 Hz, 1H), 2.97 (dd,J= 18.4, 9.6 Hz, 1H), 2.62 (dd,J= 18.4, 5.6 Hz,1H), 1.36 (s, 3H), 1.29 (s, 3H).。
P-5, [α]D 25= +6.0 (c= 1.0, CHCl3);1H NMR (600MHz, CDCl3) δ 9.46 (s, 1H), 8.35 – 8.29 (m, 2H), 7.61 – 7.54 (m, 2H), 3.10(dd,J= 9.6, 5.4 Hz, 1H), 3.00 (dd,J= 18.6, 9.6 Hz, 1H), 2.65 (dd,J= 18.6, 5.4Hz, 1H), 1.41 (s, 3H), 1.30 (s, 3H).。/>
P-6, [α]D 25 = +5.0 (c= 1.0, CHCl3);1H NMR (600MHz, CDCl3) δ 9.52 (s, 1H), 7.21 – 7.15 (m, 2H), 6.99 – 6.95 (m, 2H), 3.82(s, 3H), 3.13 (dd,J= 9.6, 5.4 Hz, 1H), 2.96 (dd,J= 18.4, 9.6 Hz, 1H), 2.60(dd,J= 18.6, 5.4 Hz, 1H), 1.32 (s, 3H), 1.28 (s, 3H).。
P-7, [α]D 25= +6.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.52 (s, 1H), 7.27 (d,J= 7.2 Hz, 2H), 7.14 (d,J= 8.4 Hz, 2H), 3.14(dd,J= 9.6, 5.4 Hz, 1H), 2.97 (dd,J= 18.4, 9.6 Hz, 1H), 2.61 (dd,J= 18.4, 5.5Hz, 1H), 2.37 (s, 3H), 1.32 (s, 3H), 1.28 (s, 3H).。
P-8, [α]D 25= +20.0 (c= 1.0, CHCl3); 1H NMR (600 MHz,CDCl3) δ 9.63 (s, 1H), 7.48 (t,J= 7.8 Hz, 2H), 7.40 (t,J= 7.5 Hz, 1H), 7.34 –7.28 (m, 2H), 3.31-3.26 (m, 1H), 3.12 – 3.06 (m, 1H), 2.93 (dd,J= 18.0, 9.7Hz, 1H), 2.60 (dd,J= 18.0, 5.7 Hz, 1H), 1.40 (d,J= 7.8 Hz, 3H).。
P-9, [α]D 25 = +16.0 (c= 1.0, CHCl3); 1H NMR (600 MHz,CDCl3) δ 9.78 (s, 1H), 7.50 – 7.45 (m, 2H), 7.41 – 7.36 (m, 1H), 7.31-7.28(m, 2H), 3.17 (dd,J= 7.2, 3.7 Hz, 1H), 3.11 – 2.99 (m, 1H), 2.87 (dd,J= 18.0,9.6 Hz, 1H), 2.73 (dd,J= 18.0, 6.0 Hz, 1H), 2.36 – 2.28 (m, 1H), 1.26 (d,J=6.6 Hz, 3H), 1.10 (d,J= 6.6 Hz, 3H).。
P-10, [α]D 25= +41.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.75 (s, 1H), 7.47 (t,J= 6Hz, 2H), 7.41-7.37 (m, 1H), 7.32-7.26 (m,2H), 3.36-3.32 (m, 1H), 3.03 – 2.96 (m, 2H), 2.57 (dd,J= 18.0, 5.4 Hz, 1H),1.94-1.88 (m, 1H), 1.70-1.62 (m, 1H), 1.51 – 1.45 (m, 2H), 1.42-1.36 (m, 2H),0.93 (t,J= 6 Hz, 3H).。
P-11, [α]D 25= -40.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.39 (s, 1H), 7.49-7.46 (m, 2H), 7.40-7.37 (m, 1H), 7.34 – 7.29 (m,2H), 3.05-2.94(m, 2H), 2.58 (dd,J= 18, 5.4 Hz, 1H), 2.37 – 2.27 (m, 1H), 2.14– 2.03 (m, 2H), 1.88 – 1.69 (m, 5H).。
P-12, [α]D 25= -5.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.55 (s, 1H), 7.47 (t,J= 7.7 Hz, 2H), 7.40-7.38 (m, 1H), 7.31 – 7.27(m, 2H), 3.22 (dd,J= 9.0, 6.0 Hz, 1H), 2.87 (dd,J= 18.0, 9.6 Hz, 1H), 2.68(dd,J= 18.2, 5.9 Hz, 1H), 1.99 – 1.85 (m, 3H), 1.67 – 1.49 (m, 6H).。
P-13, [α]D 25= +10.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.63 (s, 1H), 7.47 (t,J= 7.8 Hz, 2H), 7.39 (t,J= 7.5 Hz, 1H), 7.29 –7.25 (m, 2H), 3.25 (dd,J= 9.6, 6.0 Hz, 1H), 2.97 (dd,J= 18.4, 9.6 Hz, 1H),2.69 (dd,J= 18.4, 6.0 Hz, 1H), 2.02 – 1.83 (m, 3H), 1.74 (dq,J= 15.0, 7.5 Hz,1H), 1.03 – 0.97 (m, 6H).。
P-14, [α]D 25= -9.0 (c= 1.0, CHCl3);1H NMR (600 MHz, CDCl3)δ 9.51 (s, 1H), 3.04 (dd,J= 9.6, 5.4 Hz, 1H), 2.99 (s, 3H), 2.82 (dd,J= 18.3,9.4 Hz, 1H), 2.45 (dd,J= 18.3, 5.4 Hz, 1H), 1.22 (d,J= 6.4 Hz, 6H).。
P-15, [α]D 25= -11.0 (c= 1.0, CHCl3);1H NMR (600 MHz,cdcl3) δ 9.51 (s, 1H), 3.98 – 3.91 (m, 1H), 2.97 (dd,J= 9.5, 5.2 Hz, 1H),2.74 (dd,J= 18.3, 9.5 Hz, 1H), 2.37 (dd,J= 18.3, 5.2 Hz, 1H), 2.16-2.08 m,2H), 1.80 (d,J= 13.4 Hz, 2H), 1.66-1.53 (m, 3H), 1.32-1.23 (m, 2H), 1.23 –1.12 (m, 7H).。
P-16, [α]D 25= -14.0 (c= 1.0, CHCl3);1H NMR (600MHz, CDCl3) δ 9.48 (s, 1H), 7.37 – 7.34 (m, 2H), 7.31-7.28 (m, 2H), 4.65 (q,J= 14.4 Hz, 2H), 3.03 (dd,J= 9.4, 5.4 Hz, 1H), 2.81 (dd,J= 18.3, 9.4 Hz, 1H),2.45 (dd,J= 18.3, 5.4 Hz, 1H), 1.16 (d,J= 2.3 Hz, 6H).。
P-17, [α]D 25 = +5.0 (c= 1.0, CHCl3);1H NMR (600 MHz,CDCl3) δ 9.46 (s, 1H), 8.81 (s, 1H), 3.07 (dd,J= 9.6, 5.4 Hz, 1H), 2.83 (dd,J= 18.4, 9.6 Hz, 1H), 2.48 (dd,J= 18.4, 5.4 Hz, 1H), 1.21 (d,J= 6.9 Hz, 6H).。/>
Claims (3)
1.一种如式1示四肽化合物TP-3,
,
其中R1和R2分别是C1 ~ C4的任意直链烷基、支链烷基、环己基、苯基、苯甲基中的任一种,其特征在于R1 = Ph, R2 = i-Bu,其氨基酸序列为H2N-D-Phg-Pro-Gly-D-Leu-OH,命名为TP-3。
2.权利要求1所述化合物TP-3的制备方法,其特征在于:
1)如式2或式3或式4或式5或式6中任一反应制备出化合物3a,
;
2)再以式7或式8或式9中任一方法制备出化合物4a,
;
3)再以式10和式11示反应历程制备得到化合物7a,
;
4)以式12示反应制备得到化合物9c,
;
5)再以式13和式14示反应历程制备得到目标化合物化合物TP-3,
3.权利要求1所述的四肽化合物用于催化脂肪醛与马来酰亚胺的不对称共轭加成反应。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310678726.XA CN116535461A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-3及制备方法和用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310678726.XA CN116535461A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-3及制备方法和用途 |
CN201811616048.XA CN109517032B (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物及制备方法和用途 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811616048.XA Division CN109517032B (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物及制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116535461A true CN116535461A (zh) | 2023-08-04 |
Family
ID=65797396
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310683686.8A Pending CN116535462A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-6及制备方法和用途 |
CN202310677733.8A Pending CN116655732A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-2及制备方法和用途 |
CN202310679549.7A Pending CN116836224A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-5及制备方法和用途 |
CN201811616048.XA Active CN109517032B (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物及制备方法和用途 |
CN202310679261.XA Pending CN116574155A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-4及制备方法和用途 |
CN202310678726.XA Pending CN116535461A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-3及制备方法和用途 |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310683686.8A Pending CN116535462A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-6及制备方法和用途 |
CN202310677733.8A Pending CN116655732A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-2及制备方法和用途 |
CN202310679549.7A Pending CN116836224A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-5及制备方法和用途 |
CN201811616048.XA Active CN109517032B (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物及制备方法和用途 |
CN202310679261.XA Pending CN116574155A (zh) | 2018-12-27 | 2018-12-27 | 一种四肽化合物tp-4及制备方法和用途 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3904367A4 (zh) |
CN (6) | CN116535462A (zh) |
WO (1) | WO2020134727A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535462A (zh) * | 2018-12-27 | 2023-08-04 | 兰州大学 | 一种四肽化合物tp-6及制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535462A (zh) * | 2018-12-27 | 2023-08-04 | 兰州大学 | 一种四肽化合物tp-6及制备方法和用途 |
-
2018
- 2018-12-27 CN CN202310683686.8A patent/CN116535462A/zh active Pending
- 2018-12-27 CN CN202310677733.8A patent/CN116655732A/zh active Pending
- 2018-12-27 CN CN202310679549.7A patent/CN116836224A/zh active Pending
- 2018-12-27 CN CN201811616048.XA patent/CN109517032B/zh active Active
- 2018-12-27 CN CN202310679261.XA patent/CN116574155A/zh active Pending
- 2018-12-27 CN CN202310678726.XA patent/CN116535461A/zh active Pending
-
2019
- 2019-11-20 EP EP19905086.5A patent/EP3904367A4/en active Pending
- 2019-11-20 WO PCT/CN2019/119628 patent/WO2020134727A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN116574155A (zh) | 2023-08-11 |
EP3904367A8 (en) | 2022-01-19 |
CN116836224A (zh) | 2023-10-03 |
WO2020134727A1 (zh) | 2020-07-02 |
CN109517032B (zh) | 2023-07-28 |
EP3904367A1 (en) | 2021-11-03 |
CN109517032A (zh) | 2019-03-26 |
EP3904367A4 (en) | 2022-09-21 |
CN116535462A (zh) | 2023-08-04 |
CN116655732A (zh) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004261329B2 (en) | Spatially-defined macrocyclic compounds useful for drug discovery | |
US11046695B2 (en) | Fragment synthesis of substituted cyclic peptides | |
CN112236436B (zh) | 一种用于溶液相肽合成的方法及其保护策略 | |
US5977302A (en) | Liquid phase process for the preparation of GnRH peptides | |
CA2325937C (en) | Peptide turn mimetics | |
CN109517032B (zh) | 一种四肽化合物及制备方法和用途 | |
Pozdnev | Activation of carboxylic acids by pyrocarbonates. Synthesis of arylamides of N‐protected amino acids and small peptides using dialkyl pyrocarbonates as condensing reagents | |
Galéotti et al. | A straightforward synthesis of α-amino phosphonate monoesters using BroP or TPyClU | |
Okumura et al. | Total Synthesis of a Macrocyclic Antibiotic, Micrococcin P. | |
US6872825B2 (en) | Peptide β-turn mimetic compounds and processes for making them | |
EP3061753A1 (en) | Enantio-selective synthesis of non-natural amino acids | |
Coin et al. | The depsipeptide technique applied to peptide segment condensation: Scope and limitations | |
JP4452329B2 (ja) | 新規テトラペプチド、その製造及び使用 | |
US5864012A (en) | Active peptide and its preparation | |
JP4878031B2 (ja) | 固相ペプチド合成法 | |
US6080838A (en) | Peptidomimetic of helix-turn-helix or gamma-turn | |
JPH09511743A (ja) | ペプチドセグメント縮合方法 | |
WO1997047313A1 (en) | Total synthesis of bacitracin polypetides | |
WO2022149584A1 (ja) | ペプチド | |
Shin et al. | Dehydrooligopeptides. XI. Facile syntheses of various kinds of dehydrodi-and tripeptides, and dehydroenkephalins containing. DELTA. Tyr residue by using N-carboxydehydrotyrosine anhydride. | |
US6350882B1 (en) | Synthesis of substituted prolines | |
Schön et al. | Ammonolysis mediated side reactions of β-tert-butyl aspartyl peptides | |
MXPA02006330A (es) | Compuestos mimeticos de peptidos de giros beta y procesos para su fabricacion. | |
WO2005042562A2 (en) | New coupling agents for peptide synthesis | |
CN117003791A (zh) | 一种二苯基膦酰氧基双酚a类化合物及其制备美白九肽-1中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |